Kalbe

About Kalbe

Kalbe is a global health care company based in Jakarta, Indonesia, established in 1966. Over the years, we have achieved market cap of US$ 5.5 Bn, managed through four business divisions: pharmaceutical, consumer health, nutritional and distribution & logistics. We look forward to explore the opportunities in: small molecules & biologics out and in-licensing;  small volume parenteral & biologics CDMO service, and natural extract supply.

Read more Show less
Certifications
  • GMP
    GMP
  • ISO
    ISO
  • Other
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • ID
  • 2018
    On CPHI since
  • 3
    Certificates
  • 5000+
    Employees
Company types
Contract Service
Distributor/Import Export
Licensee
Manufacturer/Innovator
Primary activities
Biopharmaceutical
Contract Manufacturer
Finished Formulation products Distributor/Buyer
Ingredients Distributor/Buyer
Natural Extracts
Out-licensing specialist
Pharmaceutical Company (generic finished products)
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024
View Exhibitor Profile

Products from Kalbe (5)

  • hyfc EPO (long acting)

    Product hyfc EPO (long acting)

    Efesa, is a long-acting Erythropoietin indicated for CKD-induced anemia in dialysis and non-dialysis patients. Efesa is a hybrid Fc of IgG4 and IgD that provides hinge flexibility and long serum half-life without causing toxicity to target cells. Global Phase 3 trial for non-dialysis indication is currentl...
  • Nimotuzumab

    Product Nimotuzumab

    Nimotuzumab binds with intermediate affinity and high specificity to the extracellular domain of EGFR and blocks the binding of the EGF to its receptor and inhibits tumor cell growth. The molecule induces cell lysis through ADCC mechanism. Nimotuzumab provides vaccinal effect that induce memory T-cell ...
  • Insulin Glargine

    Product Insulin Glargine

    Long-acting basal insulin analogue to treat Type I and II Diabetes Mellitus.
  • Erythropoietin Alpha

    Product Erythropoietin Alpha

    Indication: Chronic kidney diseases induced anemia (dialysis and non-dialysis)

  • Bevacizumab

    Product Bevacizumab

    Bevacizumab acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in microvascular growth of tumor blood vessels that limits the blood supply to tumor tissues.The indication is for Colorectal Cancer...

Kalbe Resources (1)